A composite analysis showing reductions in cardiac death, stroke and heart attack in Mesoblast’s Phase III heart failure trial appears to have allayed investor concerns following the December disclosure...

Samsung Biologics promoted EVP John Rim to president and CEO. Before joining the South Korean company in 2018, Rim worked for Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit for 14 years in senior global...

Increased deal flow across the board has led Forbion to split its funds between early and late-stage opportunities, with its latest €460 million ($557.7 million) fund, which closed this week, focused...

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...

Over the last three and a half years, Novartis Venture Fund has remade its team and narrowed its remit to early-stage opportunities in therapeutics. The fund’s 2020 exits suggest the strategic shift may...

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...

On the back of seven liquidity events in the past four months, Longitude Capital has closed its largest fund to date at $585 million. Managing Director Patrick Enright told BioCentury Longitude Venture Partners IV will...

The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into...

With its €380 million takeout of Dublin-based Inflazome, Roche is continuing the rush of pharmas targeting inflammasome companies in a deal that leaves NodThera as the last company standing among the first crop of high...

Novo Ventures has led a $55 million series B round for NodThera, a trans-Atlantic biotech operating in an area ripe for takeouts -- the inflammasome. The biotech's lead program targets NLRP3, a target explored by...